DexCom (NASDAQ:DXCM) Upgraded at StockNews.com

StockNews.com upgraded shares of DexCom (NASDAQ:DXCM) from a hold rating to a buy rating in a report released on Friday morning.

Several other equities research analysts have also recently commented on the company. Stifel Nicolaus upped their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. BTIG Research reduced their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Barclays dropped their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Finally, Wells Fargo & Company lifted their price target on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday. Six investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Down 1.9 %

DXCM stock opened at $73.44 on Friday. The company has a market cap of $29.21 billion, a price-to-earnings ratio of 47.38, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a fifty day moving average price of $70.11 and a 200 day moving average price of $98.24. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 24th. The medical device company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. The business had revenue of $994.20 million during the quarter, compared to the consensus estimate of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. Sell-side analysts expect that DexCom will post 1.69 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock worth $126,390 in the last ninety days. Insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds have recently made changes to their positions in the business. Team Hewins LLC boosted its stake in DexCom by 3.4% in the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after buying an additional 83 shares during the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the period. Capital Insight Partners LLC lifted its holdings in shares of DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the period. HM Payson & Co. boosted its position in shares of DexCom by 6.0% in the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in DexCom by 0.3% in the first quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock valued at $5,801,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.